

The Companies Officer  
ASX Limited  
Level 40, Central Park  
152-158 St Georges Terrace  
PERTH WA 6000


## Cleansing notice under section 708A of the Corporations Act

Recce Pharmaceuticals Ltd (**ASX:RCE**) (**Company**) issued 26,684,614 fully paid ordinary shares as detailed in the Appendix 3B released to the ASX on 16 October 2019.

The Company gives this notice under section 708A(5)(e) of the *Corporations Act 2001* (Cth) (**Corporations Act**) and states the following:

1. the abovementioned ordinary shares were issued without disclosure to investors under Part 6D.2 of the Corporations Act;
2. as at the date of this notice, the Company has complied with:
  - a) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - b) section 674 of the Corporations Act;
3. as at the date of this notice, there is no excluded information for the purposes of sections 708A(7) and 708A(8) of the Corporations Act.

For more information, please contact the undersigned on (+61) 2 8072 1400.



Alistair McKeough  
Company Secretary

For further information please visit [www.recce.com.au](http://www.recce.com.au) or contact:

### Investor Relations

James Graham  
Executive Director  
Recce Pharmaceuticals Ltd  
Tel: +61 (02) 8075 4585

### Media (Australia)

Andrew Geddes  
CityPR  
Tel: +61 (02) 9267 4511

### Media (International)

Sue Charles/Gemma Harris  
Instinctif Partners  
Tel: +44 (0)20 7866 7860  
E: [recce@instinctif.com](mailto:recce@instinctif.com)



ASX: RCE

**Head Office:** Level 36, 1 Macquarie Place, Gateway Tower, SYDNEY NSW 2000 **T** +61 (02) 8075 4585 **F** +61 (02) 8075 4584

**R&D Centre - Perth:** Suite 10, 3 Brodie Hall Drive, Technology Park, BENTLEY WA 6102 **T** +61 (8) 9362 9860

**Washington Office:** 1717 Pennsylvania Avenue NW, Suite 1025, WASHINGTON DC 20006 USA